New clinical trial shows combination of two innovative precision medicines could treat multiple cancers – News-Medical.Net

Launching a dual-pronged attack on tumours using a combination of two innovative precision medicines could treat patients with multiple common cancers, a new clinical trial shows.
It is the first trial to use the pioneering genetically targeted drug olaparib – already licensed for ovarian, breast and prostate cancer – together with a promising new medicine, called capivasertib.
The researchers used the drug combination to target two fundamental weaknesses in cancer at the same time – a damaged…

Click here to view the original article.